Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT05977231
Recruiting Observational

Efficacy of Conservative Treatments for Urinary Incontinence in Women

NCT05977231 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Mackay Medical College
Phase
Observational
Started
2023-01-01
Last updated
2023-08-04

Condition(s) studied

Urinary Incontinence

Investigational drug(s) / intervention(s)

BTbPFMTiVESBT + bPFMTBT + iVESbPFMT + iVES

BT: A program of BT (including exercise and muscle training)

bPFMT: A bPFMT program at home

iVES: An iVES program at home

BT + bPFMT: Combination of BT and bPFMT

BT + iVES: Combination of BT and iVES

bPFMT + iVES: Combination of bPFMT and iVES

Study summary

To conduct a retrospective study to examine the effect of these conservative treatments to the symptoms and quality of life of patients with urinary incontinence. The investigators will use both subjective and objective assessment parameters, such as self-report symptoms, bladder diary, pad test and urodynamic study to access the improvement.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Adult female patient diagnosed with urinary incontinence through clinical assessment * Diagnosed at Mackay Memorial Hospital and underwent non-surgical treatment and subsequent follow-up. Exclusion Criteria: * Choosing invasive or surgical treatment options (such as bladder botulinum toxin injection, urethral sling surgery). * Unable to comply with regular follow-up for at least one year. * Pregnant women * Patients with a history of neuromuscular disorders.

Primary outcome measure(s)

  • Urodynamic study (intravesical pressure) — form the baseline to the post-treatment measurement (about 6 month post)
    intravesical pressure (cmH2O)
  • Urodynamic study (abdominal pressure) — form the baseline to the post-treatment measurement (about 6 month post)
    abdominal pressure (cmH2O)
  • Urodynamic study (detrusor pressure) — from the baseline to the post-treatment measurement (about 6 month post)
    detrusor pressure (cmH2O)
  • Urodynamic study (Infused volume) — from the baseline to the post-treatment measurement (about 6 month post)
    infused volume (ml)
  • Urodynamic study (voided volume) — from the baseline to the post-treatment measurement (about 6 month post)
    voided volume (ml)
  • Pad test — from the baseline to the post-treatment measurement (about 6 month post)
    The weight of Pad (g) before and after testing
  • Bladder diary (voiding frequency) — from the baseline to the post-treatment measurement (about 6 month post)
    the daily voiding frequency (times)
  • Bladder diary (voiding volume) — from the baseline to the post-treatment measurement (about 6 month post)
    the daily voiding volume (ml)
  • Questionaire (UDI-6) — from the baseline to the post-treatment measurement (about 6 month post)
    The urogenital distress inventory-6 (UDI-6)
  • Questionaire (IIQ-7) — from the baseline to the post-treatment measurement (about 6 month post)
    incontinence impact questionnaire-7 (IIQ-7)

Trial sites (1)

FacilityCityRegionStatus
Department of Obstetrics and Gynecology New Taipei City Taiwan Recruiting

More Mackay Medical College trials in Taiwan

Efficacy/Safety of Urogynecology Synthetic Mesh Surgery Recruiting
Development of a Pregnancy Weight Management Service Model Recruiting
Efficacy/Safety of Midurethral Sling Recruiting
Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes Recruiting
SUNAM Protocol for Managing BPSD Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05977231 on ClinicalTrials.gov ↗ ← All trials in Taiwan